Erythromycin

CAS Number114-07-8
Molecular FormulaC37H67NO13
Molecular Weight733.9
InChI KeyULGZDMOVFRHVEP-RWJQBGPGSA-N
LogP2.7
Synonyms
  • erythromycin
  • 114-07-8
  • Erythromycin A
  • Abomacetin
  • Emgel
  • Erymax
  • Ilotycin
  • Eritromicina
  • Erythromycine
  • Erythromycinum
  • Robimycin
  • Eryderm
  • Erythromycin base
  • Erycette
  • Erygel
  • Sansac
  • E-Mycin
  • Erythro-Statin
  • Erythra-Derm
  • Akne-Mycin
  • ERYC
  • E-Glades
  • Ery-Tab
  • E-Base
  • Stiemycin
  • R-P Mycin
  • Eryc Sprinkles
  • E-Solve 2
  • Erythromast 36
  • T-Stat
  • Torlamicina
  • C-Solve-2
  • Erythrogran
  • Eryc 125
  • erythromycin-A
  • Erythroguent
  • Dotycin
  • Oftalmolosa Cusi Eritromicina
  • Staticin
  • Retcin
  • DTXSID4022991
  • J01FA01
  • NSC-55929
  • PCE (ERYTHROMYCIN)
  • 63937KV33D
  • DTXCID102991
  • CHEBI:42355
  • NSC55929
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
  • 7540-22-9
  • Kerymax
  • Spotex
  • Erymax sprinkle
  • Aknemycin plus
  • TStat
  • Eryacne 2
  • Eryacne 4
  • Gallimycin-36
  • T Stat
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
  • Erythro 200
  • Lactate, Erythromycin
  • Rommix 250 ec
  • Rommix 500 ec
  • Phosphate, Erythromycin
  • RefChem:6427
  • Erythro-100 Injection
  • API E.M. Erythromycin
  • Erythromycin Base Filmtab
  • GlyTouCan:G42935TE
  • Erythro-36, Erythro-Dry
  • API E.M ERYTHROMYCIN
  • CHEBI:48923
  • erythromycin topical solution 2%
  • G42935TE
  • Gallimycin Injection, Gallimycin-100
  • (2R,3S,4S,5R,6R,8R,10R,11R,12S,13R)-5-(3,4,6-Trideoxy-3-dimethylamino-beta-D-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethyl-9-oxopentadecan-13-olide
  • 204-040-1
  • 616-217-4
  • 3''-O-Demethylerythromycin
  • RP-Mycin
  • Eryacne
  • Erythrocin
  • Pantomicina
  • MFCD00084654
  • A/T/S
  • erythro
  • Ermycin
  • Erycen
  • Aknin
  • Theramycin Z
  • Ak-Mycin
  • Erytab
  • Inderm
  • Benzamycin
  • CHEMBL532
  • Dumotrycin
  • Mephamycin
  • Wemid
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
  • Erythromycin C-13
  • Endoeritrin
  • Eritomicina
  • Erythroderm
  • Erytrociclin
  • Pharyngocin
  • Proterytrin
  • Acneryne
  • Acnesol
  • Aknemycin
  • C37H67NO13
  • Derimer
  • Deripil
  • Erisone
  • Eryacnen
  • Erydermer
  • Eryhexal
  • Erysafe
  • Iloticina
  • Latotryd
  • Lederpax
  • Mercina
  • Oftamolets
  • Pantoderm
  • Pantodrin
  • Romycin
  • Stiemicyn
  • Tiprocin
  • Emuvin
  • Emycin
  • Erecin
  • Erymed
  • Erytop
  • AustriaS
  • Eros
  • Ery-maxin
  • Erythro-Teva
  • Sans-acne
  • Erimycin-T
  • Ery-Diolan
  • Inderm Gel
  • Del-Mycin
  • Aknederm Ery Gel
  • Udima Ery Gel
  • cyclotetradecane-2,10-dione
  • Emu-Ve
  • 8HPH7ND0LN
  • Skid Gel E
  • (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione
  • [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione
  • Akne Cordes Losung
  • ERY
  • Ilosone (estolate)
  • Ilotycin T.S.
  • E-Mycin (base)
  • Ery-Tab (base)
  • Emu-V
  • Ery-B
  • E-Base (base)
  • ERYC (base)
  • N-Methylerythromycin A
  • PCE Dispertab (base)
  • Eryc-125
  • Eryc-250
  • Eritromicina [INN-Spanish]
  • Erythromycine [INN-French]
  • Erythromycinum [INN-Latin]
  • Erythromycin, labeled with carbon-13
  • Staticin (TN)
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
  • Akne-mycin (TN)
  • Erygel (TN)
  • Eryc (TN)
  • T-stat (TN)
  • Pce (TN)
  • SR-05000001618
  • Sentry AQ mardel maracyn
  • Erythromycin & VRC3375
  • erthromycin
  • trahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxa
  • CCRIS 9078
  • Erythromycin RS
  • 82343-12-2
  • UNII-63937KV33D
  • HSDB 3074
  • NCGC00094670-01
  • Erythromycin [USP:INN:BAN:JAN]
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethylte
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
  • CAS-114-07-8
  • Prestwick_205
  • EINECS 204-040-1
  • Erythromycin A CRS
  • NSC 55929
  • 215031-94-0
  • Spectrum_000115
  • Spectrum_000659
  • AI3-50138
  • EM-A
  • Prestwick3_000151
  • Spectrum2_000759
  • Spectrum2_001263
  • Spectrum4_000538
  • Spectrum5_001596
  • UNII-8HPH7ND0LN
  • ERYTHROMYCIN [MI]
  • E0751
  • ERYTHROMYCIN [INN]
  • ERYTHROMYCIN [JAN]
  • EC 204-040-1
  • ERYTHROMYCIN [HSDB]
  • SCHEMBL2601
  • ERYTHROMYCIN [VANDF]
  • BSPBio_000282
  • BSPBio_002480
  • ERYTHROMYCIN [MART.]
  • KBioGR_001175
  • KBioSS_000555
  • KBioSS_001139
  • MLS001066618
  • BIDD:GT0017
  • DivK1c_000294
  • DivK1c_000397
  • DivK1c_000702
  • ERYTHROMYCIN [USP-RS]
  • ERYTHROMYCIN [WHO-DD]
  • ERYTHROMYCIN [WHO-IP]
  • SPECTRUM1500280
  • SPBio_000778
  • SPBio_001226
  • Erythromycin (mixture A,B,C)
  • BPBio1_000312
  • GTPL1456
  • orb1309999
  • orb3025580
  • Erythromycin (JP18/USP/INN)
  • HMS500O16
  • KBio1_000294
  • KBio1_000397
  • KBio1_000702
  • KBio2_000555
  • KBio2_001139
  • KBio2_003123
  • KBio2_003707
  • KBio2_005691
  • KBio2_006275
  • ERYTHROMYCIN [GREEN BOOK]
  • MSK7801
  • NINDS_000294
  • NINDS_000397
  • NINDS_000702
  • ERYTHROMYCIN [ORANGE BOOK]
  • HMS1920M04
  • HMS2091D05
  • HMS2095O04
  • HMS3712O04
  • Pharmakon1600-01500280
  • ERYTHROMYCIN [EP MONOGRAPH]
  • BB_NC-01332
  • HY-B0220
  • RKL10096
  • ERYTHROMYCIN [USP MONOGRAPH]
  • Tox21_111311
  • Tox21_111869
  • Tox21_300515
  • BDBM50344942
  • CCG-38992
  • LMPK04000006
  • MSK7801-100A
  • MSK7801-100M
  • NSC756759
  • ERYTHROMYCINUM [WHO-IP LATIN]
  • AKOS015895249
  • MSK7801-1000A
  • MSK7801-1000M
  • AE22796
  • DB00199
  • Erythromycin for system suitability CRS
  • NSC-756759
  • BENZAMYCIN COMPONENT ERYTHROMYCIN
  • IDI1_000294
  • IDI1_000397
  • IDI1_000702
  • SMP1_000119
  • NCGC00179619-01
  • NCGC00179619-02
  • NCGC00179619-03
  • NCGC00254234-01
  • AC-12744
  • AC-12901
  • Roxithromycin EP Impurity A; Erythromycin
  • SMR000544946
  • SY070227
  • Erythromycin for microbiological assay CRS
  • Erythromycin, potency: >=850 mug per mg
  • Erythromycin, tested according to Ph.Eur.
  • SBI-0051368.P003
  • Erythromycin, N-demethyl-N-(methyl-11C)-
  • Erythromycin 1000 microg/mL in Acetonitrile
  • Erythromycin Solution in Methanol, 100ug/mL
  • NS00000203
  • Third international Standard for Erythromycin
  • Erythromycin for impurity M identification CRS
  • Erythromycin Solution in Methanol, 1000ug/mL
  • Erythromycin, meets USP testing specifications
  • C01912
  • D00140
  • E-3250
  • AB00051981_09
  • AB00051981_10
  • Erythromycin Solution in Acetonitrile, 100ug/mL
  • Erythromycin, Biotechnology Performance Certified
  • 114E078
  • Erythromycin estolate impurity, free erythromycin-
  • Erythromycin Solution in Acetonitrile, 1000ug/mL
  • Q213511
  • SR-01000799155
  • Erythromycin, Antibiotic for Culture Media Use Only
  • Erythromycin, BioReagent, suitable for cell culture
  • SR-01000799155-2
  • SR-05000001618-1
  • SR-05000001618-2
  • BRD-K63550407-001-12-7
  • BRD-K63550407-001-13-5
  • BRD-K63550407-028-03-9
  • BRD-K63550407-028-04-7
  • Z2587996953
  • Erythromycin A, European Pharmacopoeia (EP) Reference Standard
  • Erythromycin, United States Pharmacopeia (USP) Reference Standard
  • ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN [EP IMPURITY]
  • ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN- [USP IMPURITY]
  • Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
  • Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
  • (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
  • (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name)
  • [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-|A-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-|A-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione
  • Erythromycin A; Dotycin; Erycin; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione

Applications:

Uv-Vis Spectrum of Erythromycin

February 18, 2026

Access the UV-Vis Spectrum SIELC Library

If you are looking for optimized HPLC method to analyze Erythromycin check our HPLC Applications library

For optimal results in HPLC analysis, it is recommended to measure absorbance at a wavelength that matches the absorption maximum of the compound(s) being analyzed. The UV spectrum shown can assist in selecting an appropriate wavelength for your analysis. Please note that certain mobile phases and buffers may block wavelengths below 230 nm, rendering absorbance measurement at these wavelengths ineffective. If detection below 230 nm is required, it is recommended to use acetonitrile and water as low UV-transparent mobile phases, with phosphoric acid and its salts, sulfuric acid, and TFA as buffers.
For some compounds, the UV-Vis Spectrum is affected by the pH of the mobile phase. The spectra presented here are measured with an acidic mobile phase that has a pH of 3 or lower.

Application Analytes:
Erythromycin
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.